Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-1 IPO registration
- 3.1 EX-3.1
- 3.4 EX-3.4
- 3.5 EX-3.5
- 4.1 EX-4.1
- 10.1 EX-10.1
- 10.7 EX-10.7
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.11 EX-10.11
- 10.12 EX-10.12
- 10.13 EX-10.13
- 10.14 EX-10.14
- 10.15 EX-10.15
- 10.16 EX-10.16
- 10.17 EX-10.17
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.20 EX-10.20
- 21.1 EX-21.1
- 23.1 EX-23.1
Associated filings
- 6 Apr 21 EFFECT Notice of effectiveness
- 1 Apr 21 POS AM Prospectus update (post-effective amendment)
- 17 Jul 20 424B4 Prospectus supplement with pricing info
- 17 Jul 20 EFFECT Notice of effectiveness
- 16 Jul 20 S-1/A IPO registration (amended)
- 13 Jul 20 S-1/A IPO registration (amended)
-
26 Jun 20 S-1 IPO registration
Pandion Therapeutics similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Registration Statement on Form S-1 of our report dated May 22, 2020, relating to the financial statements of Pandion Therapeutics Holdco LLC. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
June 26, 2020